Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29649871 | 1.00 | SLC6A2 (0.43) | SLC6A2SLC6A3SLC6A4CHRNB2CHRNA4 | |
| SCHEMBL7352894 | 0.82 | SLC6A2 (0.56) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL8205042 | 0.82 | SLC6A2 (0.56) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL7458617 | 0.82 | SLC6A2 (0.56) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL10194861 | 0.82 | SLC6A2 (0.56) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL8812053 | 0.81 | SLC6A4 (0.47) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL7560904 | 0.81 | SLC6A2 (0.58) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL7561589 | 0.81 | SLC6A4 (0.47) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL7561591 | 0.81 | SLC6A4 (0.47) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL5971564 | 0.81 | CHRM1 (0.58) | SLC6A2SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | SLC6A2 3510/4885SLC6A3 2511/4885SLC6A4 1699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.